Doctor Anywhere adds Oliver Rippel and Dr. Amit Kakar to Board along with raising SGD88m Series C financing led by Asia Partners

– SINGAPORE, Singapore –  Doctor Anywhere​, a regional tech-led healthcare company today announced that the company has raised SGD88m in a Series C financing round led by growth equity investor Asia Partners bringing the total capital raised today to more than SGD140m.

The round also attracted other investors including Novo Holdings, Philips, and OSK-SBI Venture Partners.

Concurrent with the financing, Oliver Rippel, Co-Founder and Partner of Asia Partners, and Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Equity Asia will join the Board of Directors.

At SGD 88 million (US$65.7 million), it is one of the largest private funding rounds ever raised by a healthtech company in Southeast Asia.

Existing investors also participated in the round, including Singapore-based global investor EDBI, Square Peg, IHH Healthcare, Kamet Capital, and Pavilion Capital.

Lim Wai Mun, founder, and CEO of Doctor Anywhere said: “DA’s mission is to be the largest tech-enabled omnichannel healthcare provider in Southeast Asia, and applying innovative technology to improving patient outcomes is core to our differentiated offerings. We are thrilled to attract the interest of a strong group of investors in this round, a significant milestone which is a testament to our vision and track record.”

“We will utilize this funding to further enhance our digital capabilities, and scale upon our ability to deliver quality healthcare seamlessly to our users in Southeast Asia,” added Lim.

“We are deeply impressed by what Wai Mun and his team have accomplished in such a short period of time,” said Oliver Rippel, a co-founder of Asia Partners. “As our region’s leading omnichannel healthcare innovator, DA is helping the healthcare industry rise to the occasion for the challenges and opportunities in the decade ahead. We are proud to be partnering with DA to support its continued growth.”

Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Equity Asia, said: “We are very pleased to invest in DA and to support its mission to transform the regional healthcare landscape through technology. The pandemic accelerated a trend that was already gaining traction – the delivery of high quality, cost-effective, and highly accessible healthcare through digital means, regardless of where the patients are located. DA offers a leading approach to combining the online and offline realms of healthcare through an omnichannel strategy, bringing the delivery of patient care to the next level of tech-led healthcare. We look forward to leveraging this momentum and continuing to work with Wai Mun and his team, true leaders in this space.”

About Doctor Anywhere

Doctor Anywhere is a regional tech-enabled, omnichannel healthcare company, on mission is to make healthcare simple, accessible, and efficient for everyone. Doctor Anywhere’s digital platform bridges gaps in the healthcare ecosystem through technology and innovation, enabling users to manage their health easily and effectively through the DA mobile app. Headquartered in Singapore and with a presence in six countries across the region, Doctor Anywhere now serves more than 1.5 million (and growing) users across Southeast Asia.

Doctor Anywhere is currently available in Singapore, Malaysia, Thailand, Vietnam, and the Philippines. The group also recently announced the establishment of regional tech hubs in Bangalore, India, and Ho Chi Minh City, Vietnam.

For more information:

About Asia Partners

Based in Singapore, Asia Partners is a growth equity investment firm focused on technology and technology-enabled companies. Its US$384M fund, announced in March 2021, is the largest debut technology fund in Southeast Asia’s history and included limited partners from six continents. Before co-founding Asia Partners, the Firm’s six co-founders played leadership roles in Southeast Asia across Naspers, Sea Ltd, Bukalapak, eBay, and Vinamilk.

About Novo Holdings

Based in Denmark, Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.